PFENEX INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 9th, 2019 • Pfenex Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is entered into by and between Pfenex Inc. (the “Company”), and Martin Brenner (“Executive”). This Agreement will be effective as the date Executive commences employment with the Company (the “Effective Date”). It is expected that the Effective Date will be March 18, 2019.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Mena Development and License Agreement • May 9th, 2019 • Pfenex Inc. • Pharmaceutical preparations • New York
This MENA Development and License Agreement (this “Agreement”) is entered into as of February 25, 2019 (the “Effective Date”) by and between Pfenex Inc., a Delaware corporation (“Pfenex” or a “Party”), and Alvogen Malta (Out-Licensing) Ltd., a Maltese corporation (“Alvogen” or a “Party”, and together with Pfenex, the “Parties”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...e.u. Development and License Agreement • May 9th, 2019 • Pfenex Inc. • Pharmaceutical preparations • New York
This E.U. Development and License Agreement (this “Agreement”) is entered into as of February 25, 2019 (the “Effective Date”) by and between Pfenex Inc., a Delaware corporation (“Pfenex” or a “Party”), and Alvogen Malta (Out-licensing) Ltd., a Maltese corporation (“Alvogen” or a “Party”, and together with Pfenex, the “Parties”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Development and License Agreement • May 9th, 2019 • Pfenex Inc. • Pharmaceutical preparations • New York
This Development and License Agreement (this “Agreement”) is entered into as of February 25, 2019 (the “Effective Date”) by and between Pfenex Inc., a Delaware corporation (“Pfenex” or a “Party”), and Alvogen Malta (Out-Licensing) Ltd., a Maltese corporation (“Alvogen” or a “Party”, and together with Pfenex, the “Parties”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Development and License Agreement • May 9th, 2019 • Pfenex Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 to the Development and License Agreement (this “Amendment”) is effective this 25th day of February 2019 (the “Amendment Effective Date”) by and between Pfenex Inc., a Delaware corporation (“Pfenex”), and Alvogen Malta Operations Ltd., a Maltese corporation (“Alvogen”). Pfenex and Alvogen are sometimes collectively referred to herein as the “Parties” and separately as a “Party.”
